Value of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Previous Excisional Biopsy by Coskun, Gokhan et al.
© 2012 Korean Breast Cancer Society. All rights reserved.  http://ejbc.kr  |  pISSN 1738-6756   
eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Axillary dissection, in the treatment of breast cancer, does 
not provide significant survival advantage in patients with 
negative axilla. However, it is useful for the assessment of 
prognosis and determining adjuvant therapy [1,2]. Sentinel 
lymph node biopsy (SLNB) in breast cancer patients with 
clinically negative axilla will ensure axillary dissection only for 
cases with lymph node metastasis and will provide informa-
tion about pathologic staging as accurate as the axillary dissec-
tion, to reduce the morbidity and cost of axillary lymph node 
dissection (ALND). Therefore, SLNB is used as a staging pro-
cedure in patients with early-stage breast cancer instead of 
ALND [3,4]. 
Removal of the primary tumor with excisional biopsy may 
impair breast lymphatics. It used to be thought that success of 
SLNB following excisional biopsy is low [5,6]. However, studies 
have shown that it could be successfully performed regardless 
of the type of initial biopsy, the volume of excision, and the time 
between biopsy and SLNB [7-9]. The aim of this study was to 
investigate the feasibility of SLNB after excisional biopsy.
METHODS
Patients previously diagnosed with excisional biopsy or guide 
wire-localization and operated with SLNB between February 
2007 and March 2009 were retrospectively analyzed in this 
study. Patients with clinically or radiologically positive axilla, 
treated with neoadjuvant chemotherapy and/or radiotherapy, 
and diagnosed with fine needle aspiration biopsy (FNAB) were 
excluded from the study.
SLNB was performed with 10 cc of 1% methylene blue alone 
or both methylene blue and 1 mCi of Tc-99m nanocolloid 
combination. Injections were given both subdermally around 
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Purpose: Sentinel lymph node biopsy (SLNB) in breast cancer 
patients with clinically negative axilla will ensure axillary dissection 
only for cases with lymph node metastasis and provide informa-
tion about pathologic staging as accurate as the axillary dissec-
tion. It was shown that SLNB could be successfully performed 
regardless of the type of biopsy. The aim of this study was to     
investigate the feasibility of SLNB after excisional biopsy. Methods: 
One hundred patients diagnosed with excisional biopsy or guide 
wire-localization and operated on with SLNB between February 
2007 and March 2009 were retrospectively analyzed. SLNB was 
performed with 10 cc of 1% methylene blue alone or both meth-
ylene blue and 1 mCi of Tc-99m nanocolloid combination. Age, 
tumor localization and size, length of the biopsy incision, size of 
the biopsy specimen, multifocality, lymphovascular invasion,     
tumor grade, staining with methylene blue, localization, number 
and metastatic status of the lymph nodes stained, and success 
rate with a gamma probe were evaluated. Results: Sentinel 
lymph node (SLN) could not be identified in 9 (16.9%) of patients 
in the methylene blue group (n=53). In the combination group 
(n=47), SLN could not be identified in one patient. Of 32 patients 
with negative SLNB, metastatic involvement was found to be 
present in 5 patients after axillary lymph node dissection (false 
negatives). The average numbers of SLNs found in the methylene 
blue group and combination group were 1.4 and 1.6, respective-
ly. SLN detection and false negative rates in the methylene blue 
group were 83% and 15.7%, respectively. The rates for the com-
bination group were 98% and 6.4%, respectively. None of the 
parameters related to patient, tumor or process were found to 
affect detection rates of SLN. Conclusion: Only SLNB using a 
combination method is a safe and reliable technique for breast 
cancer patients diagnosed with excisional biopsy. 
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the biopsy incision and in the periareolar region. The radio- 
active substance was given 2-18 hours before the operation, 
and preoperative lymphoscintigraphy was used for all patients. 
A gamma probe was used for all patients labeled with radio-     
active iodine. Methylene blue was administered in 10 minutes 
before the skin incision was performed and manual massage 
was performed for 5 minutes. All blue and/or radioactive lymph 
nodes were considered as sentinel nodes. As the accuracy of 
this procedure is usually confirmed with axillary dissection in 
many studies in the literature, standard level I and II ALND 
was performed for all patients after SLNB. 
Age, tumor localization, tumor size, length of the biopsy   
incision, size of the biopsy specimen, multifocality, lympho-
vascular invasion, tumor grade, staining with methylene blue, 
localization, number and metastatic status of the lymph nodes 
stained, and success rate with a gamma probe and metastasis 
were evaluated for every patient. Effects of these factors on the 
successful localization of SLN and false negativity were evalu-
ated with a chi-square test using SPSS for Windows version 
13.0 program (SPSS Inc., Chicago, USA). A p<0.05 value was 
considered as statistically significant. 
RESULTS
One hundred patients were evaluated in this study. Mean 
age of the patients was 49.8 years (range, 27-74 years). Eighty 
patients with palpable tumors were diagnosed with excisional 
biopsy and 20 with excisional biopsy directed by guide wire 
localization. Median length of the biopsy incision was 3 cm, 
median length of the long axis of the biopsy specimen was 4 cm, 
and average tumor size was 2.9 cm. Multifocal tumors were 
reported in 11 patients. Tumors of 52 patients were located in 
the upper lateral quadrant, 22 patients in the lower lateral quad-
rant, and 8 patients in the central region. The average time   
period between excisional biopsy and definitive surgery was 
18.5 days (range, 9-27 days). There were no allergic reactions, 
dermal necrosis or fibrosis related to the methylene blue or 
radiocolloid.
Fifty-three patients were given 10 cc of 1% methylene blue 
alone and the remaining 47 were given methylene blue and 1 
mCi of Tc-99m nanocolloid. SLNs could not be identified in 9 
patients in the group where only methylene blue was admin-
istered (16.9%). Of the 32 patients with a negative SLNB, me- 
tastatic involvement was found in 5 patients after ALND (false 
negativity). In the combination group, SLN could not be iden-
tified in 1 patient. In this group, metastatic lymph nodes were 
detected in 2 patients after ALND out of 31 patients where SLN 
was negative. In the combination group, there was no staining 
with methylene blue in 3 patients. A SLN was found with the 
help of methylene blue in 2 of 3 patients that SLN could not 
be defined with gamma probe. SLN could not be visualised in 
only one of the lymphoscintigraphies. The average numbers 
of SLNs found in the methylene blue group and combination 
group were 1.4 and 1.6, respectively. Multiple SLNs were found 
in 51% of the cases in the combination group and in 49% of 
the cases in the methylene blue group. Numbers of lymph nodes 
in groups with methylene blue and gamma probe are shown 
in Table 1. Unusual localization of a SLN was level 2 in one 
patient, and mammaria interna in one patient. SLN detection 
and false negative rates in the methylene blue group were 83% 
and 15.7%, respectively. These rates for the combination group 






 SLNs detected with
gamma probe (n=47)
No. (%)
0 12 (12)    3 (6.3)
1 40 (40)    20 (42.5)
2 27 (27) 16 (34)




SLN=sentinel lymph node; LN=lymph node.
Table 2. Accuracy of SLNB with different techniques




 Total  
 No. (%)
No. of patients 53 (53) 47 (47) 100
Rate of SLN finding 44/53 (83) 46/47 (98) 90/100 (90)
SLN negative 32 (72.7) 31 (67.3) 63 (70)
Negative predictive value 27/32 (84.3) 29/31 (93.6) 56/63 (88.9)
False negative 5/32 (15.7) 2/31 (6.4) 7/63 (11.1)
Only SLN positive 4/12 (33.3) 3/16 (18.7) 7/28 (25)
Sensitivity 8/13 (62) 13/15 (86.6) 21/28 (75)
Specificity 27/31 (87) 29/32 (90.6) 56/63 (88.9)
Accuracy rates 35/44 (80) 42/46 (91.3) 77/90 (85.6)
SLNB=sentinel lymph node biopsy; MB=methylene blue; RC=radiocolloid; 
SLN=sentinel lymph node.
Table 3. The results of the parameters that statistically analyzed
SLN can be 
found (n=90)
SLN can not be 
found (n=10)
p-value
Age (yr) 49.7±9.3 50.7±9.8 0.32
Length of incision (cm) 2.98 (1.5-4) 3.16 (1.4-4.3) 0.09
Size of biopsy specimen (cm) 3.98 (2.2-6.8) 4.12 (2.5-7.1) 0.44
Tumor size (cm) 2.89±0.6 2.98±0.7 0.31
Time to surgery (days) 20.3±4.1 18.1±3.8 0.08
Multifocality (%) 11.1 10 0.43
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were 98% and 6.4%, respectively (Table 2). Sensitivity and spec-
ificity rates and negative predictive values for the methylene 
blue and combination techniques were given in Table 2.
None of the parameters related to patient, tumor or process 
was found to affect the detection rate of SLN (Table 3).
DISCUSSION
The triple test consisting of physical examination, mammo- 
graphy, and percutaneous biopsy is the gold standard for the 
diagnosis of breast lesions [10]. In case of suspicion of the       
diagnosis in the tests, the diagnosis should be confirmed with 
excisional biopsy. Since the facilities for percutaneous biopsy 
of non-palpable lesions are not available in every center, exci-
sional biopsy after guide-wire localization is still used for the 
diagnosis of these lesions. But the excisional biopsy impairs 
the lymphatic drainage between the tumor and axilla. As SLNB 
gained popularity, debate on the reliability of SLNB after exci-
sional biopsy started [11]. 
Many studies on reliability of SLNB following excisional     
biopsy by performing SLNB and ALND simultaneously and 
comparing it with percutaneous biopsy have been reported 
[9,12]. In a study comparing excisional biopsy and FNAB, the 
SLN detection rate and false negativity rate were not signifi-
cantly different [9]. In another study, median numbers of SLNs 
were 1.6 in patients with excisional biopsy and 1.7 in patients 
with FNAB and SLN detection rates were similar [7]. It was 
also emphasized that the time period between the excisional 
biopsy and SLNB had no effect on the localization of SLNs [13]. 
In accordance with this, the false negative rate was 8.1% with 
FNAB and 15.3% with excisional biopsy in the NSABP-32 
study [14].  
Estourgie et al. [15] examined the lymphatic drainage pat-
terns of 25 patients with lymphoscintigraphy before and after 
excisional biopsy. There were inconsistent results in 17 patients. 
The original SLN could not be visualized in 7 patients and new 
hot spots were found in 4 patients. 
Excisional biopsy may alter the lymphatics drainage tracts 
[15]. But high accuracy rates for SLNB after excisional biopsy 
are still reported [16]. It is possible that the modified lymphatic 
tracts are still draining to the original SLN. Lymphatic anatomy 
of the breast parenchyma is divided into two groups that are 
linked to each other: cutaneous lymphatics (superficial lym-
phatics) and parenchymal lypmhatics (deep lymphatics). There 
are two lymphatic networks: subepithelial plexus and subder-
mal plexus. The subepithelial lymphatic plexus in the dermis 
has no valves and is linked to the subepithelial plexus through-
out the body. Therefore, theoretically it can easily bypass the 
biopsy incision made on the skin. The subepithelial plexus is 
linked to the subdermal lymphatic labyrinth via vertical lym-
phatics. The lymphatic flow within the subdermal lymphatics 
is unidirectional, since these lymphatics do not have valves. The 
lymphatics under the areola receives its lymphatics from the 
areola and nipple and communicates with other plexuses. The 
lymph flows through the lactiferous ducts from the subareolar 
plexus to perilobular and subcutaneous lymphatics unidirec-
tionally to regional lymph nodes. Theoretically, injections to 
periareolar region must reach the original SLN even with ex-
cisional biopsies in other regions of the breast. This can explain 
high SLN detection rates that are not affected by tumor size, 
localization and the amount of tissue removed by biopsy [12].  
If drainage occurs to another lymph node, this lymph node 
can be in close proximity to the original SLN and both lymph 
nodes can have similar histopathological characteristics. Add- 
itionally, removal of more than one SLN can solve this prob-
lem. It has been shown that, while the false negative rate of a 
single SLN was 14.3%, this rate fell to 4.3% with multiple SLNs 
[9]. Success of the combined technique is also attributed to 
the removal of more SLNs. 
The combination technique and the methylene blue dye 
technique had been compared after FNAB and core breast     
biopsies [17-19], but, we could not find any literature in English 
about the use of methylene blue alone after excisional breast 
biopsy. In these studies, it was reported that the success rate of 
the combination technique was higher than methylene blue 
dye alone (100% vs. 86%) [17-20].
In another study, no difference between the success rates of 
the methylene blue and lymhazurin dyes had been reported 
[21]. But in all these studies, the false negative rates with meth-
ylene blue dye was not higher than 7%. The high false negative 
rate reported in our series (15.7%) makes this technique less 
confident. A single use of methylene blue dye isn’t reliable in 
SLNB after excisional breast biopsy.
In our series, with the use of a combined technique, the detec-
tion rate of SLNs, negative predictive value, false negativity, 
sensitivity, specificity, and accuracy rates are consistent with 
the literature and are not different from results obtained with 
percutaneous biopsy. We conclude that, only SLNB using a 
combination method is safe and reliable for breast cancer       
patients diagnosed with excisional biopsy. 
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